KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.

Ana Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, Vipul Jain, Abdallah Khemis, Mark Lebwohl, Martin Metz, Giselle Mosnaim, Michael Palumbo, Ekin Şavk, Gordon Sussman, Irena Walecka-Herniczek, Bin Yang, Claire Field, Sibylle Haemmerle, Karine Lheritier, Paula G P Machado, El-Djouher Martzloff, Noriko Seko, Pengpeng Wang, Artem Zharkov, Sarbjit Saini

J Allergy Clin Immunol 157(1) 143-154

PMID41115533
PMCID-
DOI10.1016/j.jaci.2025.09.028
发表日期2025-10-20
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, demonstrated significant improvements in disease activity over placebo in the 24-week phase 3 REMIX studies in patients with chronic spontaneous urticaria (CSU) remaining symptomatic despite second-generation H1-antihistamines. OBJECTIVE: We sought to evaluate the long-term efficacy and safety of remibrutinib in patients with CSU. METHODS: REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were two randomized placebo-controlled studies evaluating the efficacy, safety, and tolerability of remibrutinib in patients with CSU. Patients were randomized 2:1 to receive oral remibrutinib 25 mg twice daily or placebo during a 24-week double-blind placebo-controlled period, followed by a 28-week open-label treatment period (up to 52 weeks). The primary end point was change from baseline in weekly Urticaria Activity Score at week 12. RESULTS: A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive remibrutinib (n = 313 and 300, respectively) or placebo (n = 157 and 155, respectively). At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score (mean [95% confidence interval], REMIX-1: -23.22 [-24.78, -21.66]; REMIX-2: -22.98 [-24.51, -21.44]), with similar responses observed in patients who transitioned from placebo to remibrutinib at week 24 (observed as early as 1 week after transitioning). Exposure-adjusted incidence rates of adverse events, serious adverse events, and adverse events leading to discontinuation with 52-week remibrutinib treatment remained equivalent to those in the 24-week analysis. CONCLUSION: Remibrutinib showed sustained efficacy and a consistent, favorable long-term safety profile in patients with CSU remaining symptomatic despite second-generation H1-antihistamines.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。